ArticleAntimicrobial agents and chemotherapy2008
Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 104 citations in OpenAlex.
- Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.Antimicrobial agents and chemotherapy · 2011Trial
- A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?Infectious diseases and therapy · 2025Review
- Vancomycin-Teixobactin Conjugates.Journal of the American Chemical Society · 2025Article
- Potent Analogues of Clovibactin from Commercially Available Amino Acid Building Blocks.The Journal of organic chemistry · 2025Article
- Article
- Investigation of Isobactin Analogues of Teixobactin.ACS medicinal chemistry letters · 2024Article
- Twenty Years in EUCAST Anti-Fungal Susceptibility Testing: Progress & Remaining Challenges.Mycopathologia · 2024Review
- Potent synergy and sustained bactericidal activity of polymyxins combined with Gram-positive only class of antibiotics versus four Gram-negative bacteria.Annals of clinical microbiology and antimicrobials · 2024Article
- Isobactins:Chemical science · 2022Article
- New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.Antimicrobial agents and chemotherapy · 2022Review
- Development of a Broth Microdilution Method for Exebacase Susceptibility Testing.Antimicrobial agents and chemotherapy · 2021Article
- The genome insights of Streptomyces lannensis T1317-0309 reveals actinomycin D production.The Journal of antibiotics · 2020Article
- Design, Synthesis, and Study of Lactam and Ring-Expanded Analogues of Teixobactin.The Journal of organic chemistry · 2020Article
- Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.Frontiers in cellular and infection microbiology · 2020Review
- Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.Journal of clinical microbiology · 2019Review
- Oritavancin polymethylmethacrylate (PMMA)-compressive strength testing and in vitro elution.Journal of orthopaedic surgery and research · 2019Article
- Plastic binding feature of polymyxins: the effect on MIC susceptibility measurements.Infection and drug resistance · 2019Article
- Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays.Antimicrobial agents and chemotherapy · 2019Article
- Evaluation of Non-Tissue Culture- versus Tissue Culture-Treated Microplates for Oritavancin Susceptibility Testing.Journal of clinical microbiology · 2018Article
- Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.Infectious diseases and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oritavancin, a semisynthetic lipoglycopeptide with activity against gram-positive bacteria, has multiple mechanisms of action, including the inhibition of cell wall synthesis and the perturbation of the membrane potential. Approved guidelines for broth microdilution MIC assays with dalbavancin, another lipoglycopeptide, require inclusion of 0.002% polysorbate 80. To investigate the potential impact of polysorbate 80 on oritavancin susceptibility assays, we quantified the recovery of [(14)C]oritavancin from susceptibility assay plates with and without polysorbate 80 and examined the effect of the presence of polysorbate 80 on the oritavancin MICs for 301 clinical isolates from the genera Staphylococcus, Enterococcus, and Streptococcus. In the absence of polysorbate 80, [(14)C]oritavancin was rapidly lost from solution in susceptibility assay test plates: 9% of the input drug was recovered in broth at 1 h when [(14)C]oritavancin was tested at 1 mug/ml. Furthermore, proportionately greater losses were observed at lower oritavancin concentrations, suggesting saturable binding of oritavancin to surfaces. The inclusion of 0.002% polysorbate 80 or 2% lysed horse blood permitted the recovery of 80 to 100% [(14)C]oritavancin at 24 h for all drug concentrations tested. Concordantly, oritavancin MIC(90)s for streptococcal isolates, as determined in medium containing 2% lysed horse blood, were identical with and without polysorbate 80. In stark contrast, polysorbate 80 reduced the oritavancin MIC(90)s by 16- to 32-fold for clinical isolates of enterococci and staphylococci, which are typically cultured without blood. The results presented here provide evidence that the MIC data for oritavancin in the current literature significantly underestimate the potency of oritavancin in vitro. Moreover, the combination of data from MIC and [(14)C]oritavancin recovery studies supports the revision of the oritavancin broth microdilution method to include polysorbate 80 throughout the assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.